Regeneron Pharmaceuticals Reports Strong Q2 Growth Driven by Dupixent, EYLEA HD
Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue of $4.3 billion, a 17% increase year over year, driven primarily by strong performance from its key products including Dupixent and EYLEA HD. Non-GAAP diluted earnings per share rose to $14.29, up 11%. Dupixent sales reached $6 billion for the quarter, reflecting a 38% growth on a constant-currency basis, while EYLEA HD surpassed original Eylea in U.S. net sales for the first time. The company is also advancing its pipeline and financial flexibility by repaying its Sanofi development balance, allowing it to capture full collaboration profits moving forward. Regeneron expects continued strong performance from Dupixent but anticipates a moderation of growth due to annualization effects and tougher prior-year comparisons in the second half of 2026. EYLEA HD is expected to maintain low-to-mid-teens sequential demand growth, while original Eylea faces declining sales amid biosimilar competition. Regeneron remains focused on regulatory milestones for its products and potential expansion of its collaboration with Sanofi.